GlassScriptPhysician profile
Brandon Michael Boyd
NPI 1790430577
$2,385.39
in general payments reported to CMS, 2019-2025
26 companies · $700 in 2025
The $700 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $79.24 · 2023: $649 · 2024: $957 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $414.33 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $330.54 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $319.34 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $274.45 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $211.02 | 2023-2025 | |
| Amgen INC. | $103.22 | 2023-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.65 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $92.32 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $80.05 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.96 | 2024-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $55.25 | 2023-2025 | |
| Dynavax Technologies Corporation | $52.06 | 2024 | Heplisav-B |
| Abbott Laboratories | $47.45 | 2024-2025 | Freestyle Libre 3 |
| Zimmer Biomet Holdings, INC. | $37.60 | 2025 | Rosa |
| Phathom Pharmaceuticals, INC. | $28.36 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $24.94 | 2023 | Krystexxa |
| Astellas Pharma US INC | $20.67 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $19.58 | 2023 | Trintellix |
| Antares Pharma, INC. | $15.92 | 2023 | Xyosted, Nocdurna, Tlando |
| Shield Therapeutics INC | $15.49 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $15.00 | 2024 | |
| Medtronic, INC. | $14.63 | 2025 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $14.49 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.34 | 2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $13.79 | 2023 | Camzyos |
| Halozyme INC | $12.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.